. Author manuscript; available in PMC: 2015 Nov 1.

Published in final edited form as: Br J Haematol. 2014 Aug 12;167(4):500–505. doi: 10.1111/bjh.13067

Table I.

Clinical characteristics of the previously treated MM patients with actively relapsing disease based on the presence of 100 or more cPCs

Variables	Less than 100 cPCs (N = 92)	100 or more cPCs (N=53)	P - value
Age (years)	65 (42 – 83)	63 (43 - 80)	0.904
PCLI	0.7 (0 – 4.2)	2.0 (0 – 16)	< 0.001
Bone marrow PC%	20 (5 - 90)	80 (5 – 100)	< 0.001
LDH (u/l)	175 (75 - 605)	203 (79 – 2048)	0.012
Beta-2-microglobulin (mg/l)	3.0 (1.5 – 12.7)	6.7 (2.0 – 27.3)	< 0.001
Creatinine (μmol/l)	88.4 (35.4 – 247.5)	97.2 (53.0 – 592.3)	0.070
Albumin (g/l)	34 (26 - 42)	35 (16 – 43)	0.333
FISH (No of patients available) High risk FISH *t(4,14)* *t(14,16)* *t(14,20)* *Deletion 17p*	Available in 66 patients 17 (26%) 8 (12%) 1 (2%) 0 (0%) 11 (17%)	Available in 36 patients 14 (39%) 1 (3%,) 5 (14%) 1 (3%) 11 (31%)	0.184
Prior therapies received (n) Prior novel agents received *-Thalidomide* *-Lenalidomide* *-Bortezomib* Prior ASCT	3 (1-11) 89 (97%) 31 (34%) 73 (79%) 58 (63%) 59 (64%)	4 (1-10) 51 (96%) 25 (47%) 42 (79%) 38 (72%) 31 (59%)	0.329 0.150 0.594

MM, multiple myeloma; PC%, plasma cell percentage; cPCs, circulating plasma cells; PCLI, plasma cell labelling index; LDH, lactate dehydrogenase; FISH, fluorescent in-situ hybridization; ASCT, autologous stem cell transplantation.